What is a common toxicity associated with Ipilimumab?

Ipilimumab is an immune checkpoint inhibitor that primarily targets CTLA-4, enhancing the immune response against cancer cells. A significant and well-documented toxicity associated with Ipilimumab is liver toxicity, also known as hepatotoxicity. This occurs due to the immune system's activation against normal liver cells, leading to inflammation and potential damage.

Patients receiving Ipilimumab may experience elevated liver enzymes, indicating liver inflammation, which can range from mild to severe. Monitoring liver function tests is crucial during treatment to detect any abnormalities early and manage them appropriately. This toxicity aligns with the expected adverse effects of therapies that modulate the immune system, as they can potentially lead to unintentional immune-mediated damage to various organs.

In contrast, while peripheral neuropathy, bone marrow suppression, and cardiovascular toxicity can occur with different cancer treatments, they are not the primary concerns with Ipilimumab specifically. These other toxicities are more characteristic of chemotherapy agents or different classes of immunotherapies, rather than Ipilimumab itself. Therefore, liver toxicity is notably the most relevant associated risk for this particular drug.